FIGURE 1.
Dose‐normalized plasma galunisertib concentrations at steady state (following treatment on day 14) with monotherapy (Part A) and combination with ramucirumab (Part D)
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.